Pharmacokinetics

Björkman, Sven

doi:10.1002/9781118398258.ch16

Textbook of Hemophilia 2014

DOI: 10.1002/9781118398258.ch16

|View full text |Cite

Pharmacokinetics

Sven Björkman¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 40 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A

Castaman¹,

Linari²

2017

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

The prevention of bleeding by prophylactic factor replacement is the recommended approach for the treatment of severe hemophilia. Prophylaxis should be individualized to provide the best clinical benefit to each patient. Therefore, a pharmacokinetic approach is crucial. Areas covered: This review aims to concisely describe the basic principles of pharmacokinetics of FVIII, the role of population pharmacokinetic, the available different recombinant FVIII concentrates and the new extended half-life FVIII molecules with possible improvement in hemophilia A treatment. Expert opinion: Pharmacokinetic is a useful tool to predict the outcome of replacement therapy, even though a large inter-individual variability exists, becauseof several factors: age, weight, von Willebrand factor level, blood group, active bleed, presence of inhibitors to FVIII, FVIII concentrate. Among the different recombinant FVIII concentrates pharmacokinetic differences are minor and clinically not significant. The extended half-life FVIII products brings only moderate advances, as half life extension is limited to 1.5-1.8-fold in comparison to that of native FVIII. Thus, infusions could be done every fourth, rarely fifth day to ensure a safe through level and a significant benefit can be offered only to patients treated every other day or three times weekly.

show abstract

Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A

Castaman¹,

Linari²

2017

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Pharmacokinetics

Cited by 1 publication

References 40 publications

Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A

Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A

Contact Info

Product

Resources

About